Oragenics, Inc. (LON:0A64)

Market Cap	2.07M -38.4%
Revenue (ttm)	n/a
Net Income	-8.11M
EPS	-6.41
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	38,700
Average Volume	2,415
Open	3.85
Previous Close	3.63
Day's Range	3.85 - 12.00
52-Week Range	3.63 - 74.91
Beta	n/a
RSI	45.77
Earnings Date	Mar 13, 2026

About Oragenics

Oragenics, Inc., a development-stage company, engages in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases in the United States. Its lead product is ONP-002 for the treatment of mild traumatic brain injury, a fully synthetic, non-naturally occurring neurosteroid, which is lipophilic and can cross the blood-brain barrier to reduce swelling, oxidative stress, and inflammation while restoring proper blood flow through gene amplification. The company also develops NT-CoV2-1, a SA...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1996
• Employees: 5
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0A64

Financial Performance

Financial numbers in USD